Ask AI

TROP-2 and TNBC: Personalizing Patient Care Using Current Evidence and Innovative ADC-Based Therapeutic Strategies

Video
This activity is available for 1.00 CME/CE credit(s).

Released: November 20, 2026

Expiration: May 19, 2027

See Activity Collection

In this on-demand webcast, an expert reviews evolving treatment strategies for advanced triple-negative breast cancer, focusing on the expanding role of antibody–drug conjugates (ADCs), immunotherapy, and biomarker-guided treatment selection. Drawing on clinical trial findings from KEYNOTE-355, ASCENT, ASCENT-04, ASCENT-03, and TROPION-Breast02, the discussion examines efficacy and safety outcomes with pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan, including their roles in first-line and subsequent treatment settings. The faculty also reviews how PD-L1 expression, HER2 status, prior therapies, disease characteristics, and patient-specific factors inform treatment selection and sequencing, while highlighting emerging ADCs and ongoing clinical trials. Practical considerations include recognizing and managing treatment-related adverse events, particularly neutropenia, diarrhea, stomatitis, ocular toxicity, and interstitial lung disease, to support individualized treatment decisions and optimize patient outcomes.

TROP2 and TNBC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with breast cancer do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

BD is a 50-yr-old Black woman diagnosed with de novo advanced breast cancer metastatic to the lungs and liver. Liver lesion is biopsied and reveals ER 3%, PgR 4%, HER2 negative/low (IHC 1+) with a PD-L1 22C3 CPS score of 12. Genetic testing is negative (no BRCA1/BRCA2 mutations).

What is the most appropriate therapy? 

4.

Which of the following findings was reported from the phase III ASCENT-04 trial that compared first-line sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab in patients with advanced PD-L1–positive TNBC?

5.

After how many lines of prior systemic therapy would a patient with unresectable mTNBC and underlying mucositis be a candidate for SG based on the current approval?

6.

How would you manage the first occurrence of late-onset, grade 2, noninfectious diarrhea for a patient receiving sacituzumab govitecan?